Treatment approaches to therapy-resistant depression

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Treatment-resistant depression (TRD) is characterized by diverse definitions and a lack of standardized clinical criteria, hindering therapeutic advancement.
• A significant portion of TRD stems from inadequate therapy duration or tolerability issues with tricyclic antidepressants (TCAs).
• Other factors contributing to refractory depression include comorbid medical conditions, substance abuse, specific medications, and certain depression subtypes.

Purpose of the Study:

• To review the challenges and current understanding of treatment-resistant depression.
• To explore various therapeutic strategies for managing refractory depression.
• To evaluate the efficacy of augmentation therapies, particularly lithium, in TRD.

Main Methods:

• Literature review of studies on antidepressant treatment resistance.
• Analysis of factors contributing to therapeutic failure in depression.
• Examination of evidence for various treatment modalities including selective serotonin re-uptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), electroconvulsive therapy (ECT), and augmentation strategies.

Main Results:

• Selective serotonin re-uptake inhibitors (SSRIs) offer better tolerability for patients resistant to tricyclic antidepressants (TCAs).
• Monoamine oxidase inhibitors (MAOIs) and electroconvulsive therapy (ECT) are effective options for treatment-resistant depression.
• Lithium augmentation has demonstrated clear benefits when added to both TCAs and SSRIs, with thyroid augmentation also showing promise.

Conclusions:

• Standardizing criteria for treatment-resistant depression is crucial for advancing research and clinical practice.
• A range of pharmacological and non-pharmacological interventions exist for managing refractory depression.
• Lithium augmentation is a promising strategy for enhancing antidepressant efficacy, but further research is needed to optimize its use.